ClinicalTrials.gg
Not yet recruitingNCT07883304AI-CLINICUpdated Oct 20, 2026

AI-CLINIC: A Prospective Multisite Feasibility and Safety Study of AI-Assisted Pre-Consultation History-Taking in Outpatient Cardiology

An observational study in Symptom Tracking, Cardiology and Medical History Taking, sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Observational

Updated Oct 20, 2026Newly registeredGo to Updates ↓
Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
60
Ages
18 Years and older
Sex
All
01

Study summary

An accurate medical diagnosis depends on the doctor getting a complete picture of the patient's health story, but clinic visits are short. Before some cardiology appointments, patients may be able to speak with an artificial intelligence (AI) "interviewer" - through a secure web page, usually at home - about their symptoms, medications, allergies, medical history, and what they want their doctor to understand. The AI interviewer creates a written summary for the cardiologist. It does not make diagnoses, give treatment advice, or replace the doctor: the cardiologist still takes and verifies the medical history in the usual way, and nothing written by the AI goes into the medical record without the doctor's review. In this study, 60 adults attending a first or new cardiology consultation at London Health Sciences Centre University Hospital or the London Cardiac Institute will be invited to use the AI interviewer before their appointment. Patients who prefer not to take part receive usual care. We will measure how many participants complete the interview and have a summary ready before their visit, how long the interview and the visit take, whether patients find the interviewer easy to use and feel able to explain their concerns, whether cardiologists find the summaries useful and accurate, and whether any important errors or omissions occur. Every summary is checked by the treating cardiologist, and independent physicians review all concerning cases plus a random sample. Results will show whether this workflow is feasible and safe enough to justify a larger study.

02

Conditions studied

  • Symptom Tracking
  • Cardiology
  • Medical History Taking
03

In context

Lead sponsor

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's is the lead sponsor of 327 studies on the registry; 132 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants coming into LHSC for first cardiology consultation.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 years or older.
  2. Scheduled for a first or new in-person outpatient cardiology consultation at a participating site.
  3. Able to provide free and informed consent.
  4. Able to understand the approved English Letter of Information and consent discussion; the interview and study questionnaires are conducted in English. Additional languages may be added through a future amendment with translated, Board-approved materials.
  5. Able to interact with the interviewer using a personal device or a clinic-provided iPad, with reasonable technical assistance if required.

Exclusion criteria

Exclusion Criteria:

  1. Unable to provide informed consent.
  2. Urgent or medically unstable presentation for which pre-consultation research procedures would be inappropriate or could delay care.
  3. Severe cognitive, hearing, speech, or other communication limitation preventing meaningful voice interaction despite reasonable assistance.
  4. Appointment cancelled, converted to a virtual/telephone visit, or otherwise no longer eligible before the intervention opportunity.
  5. Previous participation in AI-CLINIC.
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
60 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes

Interventions

  • OtherAI Interview

    Participants will complete an AI Interview prior to cardiology consultation used for history taking, symptom reporting and medication records prior to meeting with the physician.

06

What researchers measure

Primary outcomes

  1. Usability

    Successful completion is defined as completion of the AI interview with a readable, clinically reviewable summary generated and accessible to the treating clinician before the clinician begins the consultation. A summary is usable if not blank, corrupted, or rendered unusable by technical failure; it need not be clinically perfect. Completion may occur at home or through rescue; availability is defined independently of whether the clinician opened the summary (the attestation captures actual use). The primary analysis includes all consented participants whose eligible in-person appointment proceeds and who have an opportunity to receive the study intervention. Failure to receive, initiate, or complete the interview - including technical failure or participant refusal after consent - is counted as unsuccessful completion.

    Time frame: Baseline

Secondary outcomes

  1. 1) Patient engagement with the chatbot

    Measured by the Conversation-Turns Per Session, a validated metric defined as the total number of alternating input-output pairs during the interaction and used as a proxy for depth and fluidity of patient-chatbot interaction \[11\]. For context, CPS values typically range from 1-3 in digital assistants (such as Siri), around 9 in human dialogue, and ≥23 in advanced social chatbots such as Microsoft's Xiaolce \[25\].

    Time frame: Baseline

  2. Objective durations

    Interview duration (platform); physician-encounter duration (room-entry to room-exit, where recorded); scheduled slot length as context; summarized overall and by setting.

    Time frame: Baseline

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07883304
Responsible party
Pavel Antiperovitch (Dr. Pavel Antiperovitch, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's) — Principal investigator
First posted
Oct 20, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Oct 1, 2027 (estimated)
Completion
Jan 1, 2028 (estimated)
Last update
Oct 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion